Clinical trials
Metastatic Renal Cell Carcinoma clinical trials
Below are recruiting metastatic renal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 359 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05752552RecruitingPhase 1
Safety study of a MET-targeting pill for advanced lung cancer
This Phase 1 trial tests DO-2 to see how safe it is and how the body absorbs it (pharmacokinetics) in people with advanced or metastatic lung cancer. It is for tumors that have a specific MET exon 14 “skipping” mutation and for whom standard treatments are no longer an option.
BrusselsAges 18 years+ - NCT06869473RecruitingPhase 2
Cetuximab, chemo, and avelumab for head and neck cancer
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
Cagliari, CAGLIARIAges 18 years+ - NCT07227012RecruitingPhase 1/Phase 2
Study of a new drug for advanced liver cancer
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Irvine, CaliforniaAges 18 years+ - NCT07545967RecruitingPhase 1
Re-radiation and Chidamide for Recurrent Head and Neck Cancer
This trial tests combining re-radiation (radiation therapy given a second time) with a drug called chidamide to treat head and neck cancer that has come back after previous radiation. The goal is to see if this combination can help patients whose cancer cannot be removed by surgery or who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT06418087RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
Bologna, BOAges 18 years+ - NCT04220749RecruitingPhase 2
Radiation vs mouth surgery for HPV-negative throat cancer
This Phase 2 trial compares two standard cancer treatments—radiation or surgery through the mouth—for HPV-negative oropharyngeal throat cancer. It aims to find out which approach works better while keeping side effects and quality of life acceptable.
London, OntarioAges 18 years+ - NCT07408063RecruitingPhase 2
Study of new drug for advanced head and neck cancer
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
Toronto, OntarioAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06066333RecruitingPhase 2
Radiation and immunotherapy for adrenal cancer with liver spread
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
Basking Ridge, New JerseyAges 18 years+ - NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
New Brunswick, New JerseyAges 18 years+ - NCT06138028RecruitingPhase 2/Phase 3
Sintilimab plus chemo and radiation for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Qingdao, ShandongAges 18–80 - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05494190Recruiting
Treatment strategy for lymph node spread in hypopharyngeal cancer
This trial studies treatment choices for people with hypopharyngeal squamous cell cancer that has spread to certain neck lymph nodes. The goal is to help control the cancer in the neck and improve outcomes when the lymph node area can be surgically managed.
Harbin, HeilongjiangAges 18–75 - NCT05419089RecruitingPhase 2
Testing robotic surgery for HPV-related throat cancer patients
This Phase 2 trial studies a robotic surgery approach for certain HPV-related throat cancers, using HPV blood tests before and after surgery to guide care. If your cancer is HPV-related and your HPV blood test results match the trial targets, you may be able to join and help improve treatment for future patients.
Paramus, New JerseyAges 18 years+ - NCT07584499RecruitingPhase 1
New drug test for children with EGFR-positive solid tumors
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Guangzhou, GuangdongAges 2–18 - NCT02290145RecruitingPhase 2
Study of Cyclin D1–targeted chemotherapy before oral cancer surgery
This Phase 2 trial tests a chemotherapy plan given first (before surgery) for people with oral squamous cell carcinoma that has specific cancer markers and lymph node involvement. It aims to shrink or control the cancer so treatment after may work better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07689643RecruitingEarly Phase 1
Radioactive drug plus immunotherapy for FAP-positive lung cancer
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Wuhan, HubeiAges 18 years+ - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07070479RecruitingPhase 2
Combination treatment for PD-1 resistant nasopharyngeal cancer
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
Guangzhou, GuangdongAges 18–70 - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT04747054RecruitingPhase 3
Radiation plus pembrolizumab for newly diagnosed metastatic head and neck cancer
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
AvignonAges 18 years+
Hear when a new Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic renal cell carcinoma?
- Yes. Clin2 currently lists 359 recruiting metastatic renal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic renal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Metastatic Sarcomatoid Renal Cell Carcinoma
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
- Renal Cell Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.